Investigators hypothesize that topical tranexamic acid will have better or comparable efficacy to topical thrombin in reducing hematoma formation at the wound base. The purpose of the study is to demonstrate that topical tranexamic acid will be a non-inferior alternative medication to the current standard of care,THROMBIN-JMI® , and at a lower cost to the health system.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The number of participants with hematoma occurrence
Timeframe: Post-operative day fourteen, plus or minus two days
The rate of percentage of graft take adherence amongst participants
Timeframe: Post-operative day fourteen, plus or minus two days
Comparison of number of participants that require re-operation
Timeframe: Post-operative day fourteen, plus or minus two days